Could a common cholesterol drug help slow liver failure?
NCT ID NCT06764966
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tests whether adding the statin atorvastatin to a standard beta blocker can help people with decompensated cirrhosis, a severe form of liver disease. Fifty participants will receive either atorvastatin plus their usual beta blocker or a placebo plus beta blocker, and be followed for 12 months. The goal is to see if the combination is safe, feasible, and may reduce complications like fluid buildup or bleeding.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Atorvastatin (a statin drug) plus a non-selective beta-blocker
- What this could lead to
- If successful, this could point toward a new combination therapy to slow liver disease worsening and reduce serious complications in cirrhosis patients.
- What could go wrong
- This is a small, early pilot study with only 50 participants, so results may not apply broadly. Statins have historically been avoided in liver disease due to safety concerns, though emerging evidence suggests they may be safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Charleston Area Medical Center
RECRUITINGCharleston, West Virginia, 25304, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can everyday drugs shield the liver from Cirrhosis's worst threats?
- Could a yellow tinge predict dangerous hospital infections?
- Muscle quality on MRI may foretell liver transplant success
- Heart scans could flag Who's at risk after liver shunt
- Artificial intelligence may help decide who gets a liver first
- Melatonin may ease sleep and brain fog in liver disease — a trial puts it to the test